Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial-stage animal health company focused on developing and marketing prescription animal pharmaceuticals. Its primary product, Canalevia, is conditionally approved by the FDA for chemotherapy-induced diarrhea in dogs. The company also holds a license and co-promotion agreement with Elanco US Inc. for another veterinary product. Jaguar’s business model is predicated on the commercialization of drugs for the companion animal market, deriving revenue from the sale of these products to veterinarians and pet owners.

The company operates under a conditional FDA approval for its lead product, which permits commercialization while additional evidence of effectiveness is collected. This regulatory pathway allows for the marketing and sale of the drug for a specific labeled use in dogs before full efficacy data is established. Jaguar’s operations are intrinsically linked to the animal health sector, a commercial field dependent on the exploitation of animals for economic gain.